Drug Profile


Alternative Names: AR-18; IVV-1001; Onapristone extended-release; ZK 299; ZK 98299

Latest Information Update: 22 Aug 2016

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Arno Therapeutics; Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Class Antineoplastics; Antiprogestogens; Dimethylamines; Gonanes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Glucocorticoid receptor antagonists; Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Breast cancer; Endometrial cancer; Endometriosis; Ovarian cancer; Pregnancy; Uterine cancer

Most Recent Events

  • 16 Aug 2016 Phase-II clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)
  • 16 Aug 2016 Phase-II clinical trials in Prostate cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO)
  • 17 May 2016 Discontinued - Phase-II for Endometrial cancer and Phase-I/II for Breast cancer, Ovarian cancer, Uterine cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in France (PO) as company want to focus its recources on prostate cancer program
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top